• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺动脉高压:阿马代尔超声心动图队列的患病率和死亡率。

Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort.

机构信息

Monash University, Victoria, Australia.

出版信息

Heart. 2012 Dec;98(24):1805-11. doi: 10.1136/heartjnl-2012-301992. Epub 2012 Jul 3.

DOI:10.1136/heartjnl-2012-301992
PMID:22760869
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3533383/
Abstract

BACKGROUND

Pulmonary hypertension (PHT) lacks community prevalence and outcome data.

OBJECTIVE

To characterise minimum 'indicative' prevalences and mortality data for all forms of PHT in a selected population with an elevated estimated pulmonary artery systolic pressure (ePASP) on echocardiography.

DESIGN

Observational cohort study.

SETTING

Residents of Armadale and the surrounding region in Western Australia (population 165 450) referred to our unit for transthoracic echocardiography between January 2003 and December 2009.

RESULTS

Overall, 10 314 individuals (6.2% of the surrounding population) had 15 633 echo studies performed. Of these, 3320 patients (32%) had insufficient TR to ePASP and 936 individuals (9.1%, 95% CI 8.6% to 9.7%) had PHT, defined as, ePASP>40 mm Hg. The minimum 'indicative' prevalence for all forms of PHT is 326 cases/100 000 inhabitants of the local population, with left heart disease-associated PHT being the commonest cause (250 cases/100 000). 15 cases of pulmonary arterial hypertension/100 000 inhabitants were identified and an additional 144 individuals (15%) with no identified cause for their PHT. The mean time to death for those with ePASP >40 mm Hg, calculated from the first recorded ePASP, was 4.1 years (95% CI 3.9 to 4.3). PHT increased mortality whatever the underlying cause, but patients with PHT from left heart disease had the worst prognosis and those with idiopathic pulmonary arterial hypertension receiving disease-specific treatment the best prognosis. Risk of death increased with PHT severity: severe pulmonary hypertension shortened the lifespan by an average of 1.1 years compared with mild pulmonary hypertension.

CONCLUSIONS

In this cohort, PHT was common and deadly. Left heart disease was the most common cause and had the worst prognosis and treated pulmonary arterial hypertension had the best prognosis.

摘要

背景

肺动脉高压(PHT)缺乏社区流行率和结局数据。

目的

在超声心动图上估计肺动脉收缩压(ePASP)升高的特定人群中,确定所有形式的 PHT 的最小“指示性”流行率和死亡率数据。

设计

观察性队列研究。

地点

西澳大利亚州阿马代尔及其周边地区的居民(人口 165450 人),在 2003 年 1 月至 2009 年 12 月期间因经胸超声心动图检查而被转诊至我们单位。

结果

共有 10314 人(周边人群的 6.2%)进行了 15633 次超声心动图检查。其中,3320 例患者(32%)TR 不足以估计 ePASP,936 例患者(9.1%,95%CI 8.6%至 9.7%)存在 PHT,定义为 ePASP>40mmHg。当地人群中所有形式的 PHT 的最小“指示性”患病率为 326 例/10 万人,左心疾病相关 PHT 是最常见的原因(250 例/10 万人)。确定了 15 例肺动脉高压/10 万人,另有 144 例(15%)患者的 PHT 无明确病因。根据首次记录的 ePASP 计算,ePASP>40mmHg 患者的平均死亡时间为 4.1 年(95%CI 3.9 至 4.3)。无论潜在病因如何,PHT 都会增加死亡率,但左心疾病相关 PHT 患者的预后最差,接受特定疾病治疗的特发性肺动脉高压患者的预后最好。死亡风险随 PHT 严重程度增加而增加:严重的肺动脉高压平均使寿命缩短 1.1 年,而轻度肺动脉高压则使寿命缩短 1.1 年。

结论

在该队列中,PHT 很常见且致命。左心疾病是最常见的原因,预后最差,而接受治疗的肺动脉高压患者的预后最好。

相似文献

1
Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort.肺动脉高压:阿马代尔超声心动图队列的患病率和死亡率。
Heart. 2012 Dec;98(24):1805-11. doi: 10.1136/heartjnl-2012-301992. Epub 2012 Jul 3.
2
Pulmonary Hypertension in Central Australia: A Community-Based Cohort Study.澳大利亚中部的肺动脉高压:一项基于社区的队列研究。
Heart Lung Circ. 2019 Apr;28(4):598-604. doi: 10.1016/j.hlc.2018.02.020. Epub 2018 Mar 6.
3
Large and medium-sized pulmonary artery obstruction does not play a role of primary importance in the etiology of sickle-cell disease-associated pulmonary hypertension.大中型肺动脉梗阻在镰状细胞病相关肺动脉高压的病因中并不起主要作用。
Chest. 2008 Mar;133(3):646-52. doi: 10.1378/chest.07-1694. Epub 2008 Jan 15.
4
Determinants and prognostic significance of exercise pulmonary hypertension in asymptomatic severe aortic stenosis.无症状严重主动脉瓣狭窄患者运动性肺动脉高压的决定因素及其预后意义。
Circulation. 2012 Aug 14;126(7):851-9. doi: 10.1161/CIRCULATIONAHA.111.088427. Epub 2012 Jul 25.
5
Incidence of pulmonary hypertension in patients with systemic sclerosis and no pulmonary symptoms: is annual echocardiographic screening necessary?无肺部症状的系统性硬化症患者肺动脉高压的发病率:是否需要每年进行超声心动图筛查?
J Clin Rheumatol. 2014 Aug;20(5):268-74. doi: 10.1097/RHU.0000000000000120.
6
Association of Pulmonary Artery Pressures With Mortality in Adults With Reduced Left Ventricular Ejection Fraction.肺动脉压力与射血分数降低的成年患者死亡率的相关性。
JACC Heart Fail. 2024 May;12(5):936-945. doi: 10.1016/j.jchf.2024.01.016. Epub 2024 Mar 20.
7
Pulmonary function and diffusion capacity are associated with pulmonary arterial systolic pressure in the general population: The Rotterdam Study.一般人群中肺功能和弥散量与肺动脉收缩压相关:鹿特丹研究。
Respir Med. 2017 Nov;132:50-55. doi: 10.1016/j.rmed.2017.09.009. Epub 2017 Sep 21.
8
Prevalence, Determinants, and Prognostic Significance of Pulmonary Hypertension in Elderly Patients Admitted with Acute Decompensated Heart Failure: A Report from the BIO-HF Registry.急性失代偿性心力衰竭老年住院患者肺动脉高压的患病率、决定因素及预后意义:来自BIO-HF注册研究的报告
Echocardiography. 2015 Sep;32(9):1333-8. doi: 10.1111/echo.12857. Epub 2014 Dec 3.
9
Prevalence of Pulmonary Hypertension in the General Population: The Rotterdam Study.普通人群中肺动脉高压的患病率:鹿特丹研究
PLoS One. 2015 Jun 23;10(6):e0130072. doi: 10.1371/journal.pone.0130072. eCollection 2015.
10
Immediate and long-term results of mitral balloon valvuloplasty in patients with severe pulmonary hypertension.重度肺动脉高压患者二尖瓣球囊成形术的近期及远期疗效
J Heart Valve Dis. 2008 Sep;17(5):485-91.

引用本文的文献

1
Prevalence of Pulmonary Hypertension in Individuals With Heart Failure: A Systematic Review and Meta-Analysis.心力衰竭患者中肺动脉高压的患病率:一项系统评价和荟萃分析。
Clin Cardiol. 2025 Sep;48(9):e70197. doi: 10.1002/clc.70197.
2
Global, Regional, and National Burden of Pulmonary Arterial Hypertension Among Women of Childbearing Age, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021.1990 - 2021年育龄期女性肺动脉高压的全球、区域和国家负担:全球疾病负担研究2021的系统分析
Pulm Circ. 2025 Aug 20;15(3):e70154. doi: 10.1002/pul2.70154. eCollection 2025 Jul.
3
A structured approach for identifying disease analogs for pulmonary arterial hypertension.

本文引用的文献

1
Pulmonary pressures and death in heart failure: a community study.肺压与心力衰竭患者的死亡:社区研究。
J Am Coll Cardiol. 2012 Jan 17;59(3):222-31. doi: 10.1016/j.jacc.2011.06.076.
2
Non invasive assessment of pulmonary hypertension severity and disease progression.肺动脉高压严重程度及疾病进展的无创评估
Heart. 2011 Aug;97(15):1196-7. doi: 10.1136/hrt.2011.222471. Epub 2011 Apr 8.
3
Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis.超声心动图诊断肺动脉高压的准确性:系统评价和荟萃分析。
一种用于识别肺动脉高压疾病类似物的结构化方法。
J Manag Care Spec Pharm. 2025 Sep;31(9):909-921. doi: 10.18553/jmcp.2025.24354. Epub 2025 Jul 31.
4
Prognostic Value of Pulmonary Hypertension as an Incidental Finding Detected by Echocardiography in Patients Without Known Cardiovascular or Pulmonary Diseases.超声心动图偶然发现的肺动脉高压在无已知心血管或肺部疾病患者中的预后价值
J Clin Med. 2025 Jul 16;14(14):5044. doi: 10.3390/jcm14145044.
5
Long-term outcome of CblC deficiency complicated with pulmonary hypertension.伴有肺动脉高压的CblC缺乏症的长期预后
Orphanet J Rare Dis. 2025 Jun 4;20(1):276. doi: 10.1186/s13023-025-03839-5.
6
Association of echocardiographic pulmonary hypertension with all-cause mortality in hospitalized AECOPD patients.超声心动图诊断的肺动脉高压与住院慢性阻塞性肺疾病急性加重期患者全因死亡率的关系
Int J Cardiol Heart Vasc. 2025 Mar 29;58:101661. doi: 10.1016/j.ijcha.2025.101661. eCollection 2025 Jun.
7
Global distribution of prognostically significant pulmonary pressure indicative of pulmonary hypertension.提示肺动脉高压的具有预后意义的肺压力的全球分布情况。
J Glob Health. 2025 Mar 21;15:04098. doi: 10.7189/jogh.15.04098.
8
Systematic evaluation of subgroup analyses of inhaled treprostinil in pulmonary hypertension due to interstitial lung disease.对吸入性曲前列尼尔用于治疗间质性肺疾病所致肺动脉高压亚组分析的系统评价。
PLoS One. 2025 Feb 12;20(2):e0318739. doi: 10.1371/journal.pone.0318739. eCollection 2025.
9
Quantitative assessment of pulmonary blood flow redistribution in the classification of group 1 and group 4 pulmonary hypertension.1组和4组肺动脉高压分类中肺血流重新分布的定量评估
Quant Imaging Med Surg. 2024 Dec 5;14(12):8658-8671. doi: 10.21037/qims-24-644. Epub 2024 Nov 29.
10
Incidence of Pulmonary Hypertension in the Echocardiography Referral Population.超声心动图转诊人群中肺动脉高压的发病率。
Ann Am Thorac Soc. 2025 May;22(5):679-688. doi: 10.1513/AnnalsATS.202407-716OC.
Heart. 2011 Apr;97(8):612-22. doi: 10.1136/hrt.2010.212084. Epub 2011 Feb 25.
4
Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report.肺动脉高压患者开始联合治疗后的生存情况:澳大利亚协作报告。
Intern Med J. 2011 Mar;41(3):235-44. doi: 10.1111/j.1445-5994.2010.02403.x.
5
[Echocardiographic alterations suggestive of pulmonary hypertension in the Italian ultrasonography laboratories. Epidemiological data from the INCIPIT study (INCidence of Pulmonary Hypertension in Italian ulTrasonography laboratories)].[意大利超声检查实验室中提示肺动脉高压的超声心动图改变。INCIPIT研究(意大利超声检查实验室中肺动脉高压的发病率)的流行病学数据]
G Ital Cardiol (Rome). 2010 May;11(5):402-7.
6
Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: a systematic review of the literature.特发性肺动脉高压患者死亡率的预测因素:文献系统评价。
Respir Med. 2010 Nov;104(11):1588-607. doi: 10.1016/j.rmed.2010.08.003.
7
Pulmonary hypertension: updated classification and management of pulmonary hypertension.肺动脉高压:肺动脉高压的最新分类与管理
Heart. 2010 Apr;96(7):552-9. doi: 10.1136/hrt.2008.156299.
8
The Bosentan Patient Registry: long-term survival in pulmonary arterial hypertension.波生坦患者注册研究:肺动脉高压的长期生存情况。
Intern Med J. 2011 Mar;41(3):227-34. doi: 10.1111/j.1445-5994.2009.02139.x.
9
Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.肺动脉高压:REVEAL 注册研究的基线特征。
Chest. 2010 Feb;137(2):376-87. doi: 10.1378/chest.09-1140. Epub 2009 Oct 16.
10
Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).肺动脉高压诊断和治疗指南:欧洲心脏病学会(ESC)和欧洲呼吸学会(ERS)肺动脉高压诊断和治疗工作组,得到国际心肺移植学会(ISHLT)认可。
Eur Heart J. 2009 Oct;30(20):2493-537. doi: 10.1093/eurheartj/ehp297. Epub 2009 Aug 27.